Home/Pipeline/PTSD Discovery Programme

PTSD Discovery Programme

Post-Traumatic Stress Disorder (PTSD)

DiscoveryActive

Key Facts

Indication

Post-Traumatic Stress Disorder (PTSD)

Phase

Discovery

Status

Active

Company

Solvonis Therapeutics

About Solvonis Therapeutics

Solvonis Therapeutics is an emerging biopharma focused on developing novel treatments for high-burden CNS disorders, starting with Alcohol Use Disorder and PTSD. The company has achieved key preclinical milestones, including the selection of a lead candidate (SVN-114) for PTSD and the expansion of SVN-015 into depression, supported by recent U.S. patent allowances. Its strategy involves building a targeted pipeline through internal discovery programs, aiming to address substantial unmet medical needs with significant market potential, while navigating the challenges of a pre-revenue, public company in a nascent sector.

View full company profile

Therapeutic Areas

Addiction Psychiatry Neurology

Other Post-Traumatic Stress Disorder (PTSD) Drugs

Drug	Company	Phase	Status
AL001	Alzamend Neuro	Preclinical	Research
PES200	Virpax Pharmaceuticals	Discovery/Preclinical	Active
Sequential Dialysis Technique	Halberd	Discovery	Active Research (Gov't Funding Sought)
NeuroDirect™ Ketamine	Psycheceutical Bioscience	Phase 1	Active
Sana Device for PTSD	Sana Health	Pilot/Proof-of-Concept	Active
MDMA-assisted therapy	Lykos Therapeutics	Phase 3	Active
Neuroplastogen Programs	Delix Therapeutics	Pre-clinical	Active
TSND-201 (Methylone)	Transcend Therapeutics	Phase 2	Active
Phoenix CR	Evren Technologies	Unknown	Active
Lu AG09222	Lundbeck	Phase 2	Active
COMP360 Psilocybin Therapy	Compass Pathways	Phase 2	Active
NRX-101	NRx Pharmaceuticals	Phase 2	Investigational